Earnings Releases·Oct 29, 2026, 4:06 PM ET

DaVita Inc. — Third Quarter 2026 Earnings Summary

Consolidated revenues reached $3.578 billion; operating income declined to $499 million (14.0% margin) from $579 million (16.3% margin) in the prior quarter, while diluted EPS was $3.40 versus $3.82 adjusted.
Full-year 2026 guidance remains unchanged for adjusted operating income ($2.175B–$2.250B), adjusted diluted net income per share ($14.30–$15.20), and free cash flow ($1.000B–$1.250B).
The company repurchased 1.1 million shares for $198 million across the quarter and post-period, bringing nine-month total share repurchases to $863 million.
U.S. dialysis volume grew 0.4% normalized year-over-year, though revenue per treatment dipped $0.62 quarter-over-quarter to $415.25, while patient care costs rose $2.82 to $280.22.
A $62 million goodwill and asset impairment charge related to the China business reduced net income by $27 million, alongside ongoing management of cybersecurity incident impacts and labor market challenges.